ClinicalTrials.gg
Not yet recruitingNCT07711158Updated Jul 17, 2026

A Phase II Exploratory Study of SR604 Injection Evaluating the Safety and Efficacy in the Treatment of Congenital Coagulation Factor VII Deficiency

A Phase 2 interventional study of SR604 in Factor VII Deficiency, sponsored by Shanghai RAAS Blood Products Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-17.

Sponsored by Shanghai RAAS Blood Products Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is an open-label, multicenter, exploratory Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of SR604 Injection in patients with congenital coagulation Factor VII deficiency.

02

Conditions studied

  • Factor VII Deficiency
03

In context

Lead sponsor

Shanghai RAAS Blood Products Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥12 years and ≤65 years at the time of signing the form; both genders eligible;
  2. Clinically diagnosed with congenital coagulation Factor VII deficiency, with historical or screening FVII activity \<10%, and ≥2 treated new-onset bleeding events within 3 months prior to enrollment;
  3. No active bleeding symptoms prior to first administration of SR604 Injection;
  4. The subject and/or legal representative and impartial witness have signed the informed consent form, indicating voluntary agreement to participate in this trial, to provide biological samples for testing as required by the protocol, and to comply with the planned study visits;
  5. Female subjects (post-menarche) must have a negative serum pregnancy test (HCG) during the screening period; subjects with (females post-menarche or males post-spermarche) must agree to use highly effective measures throughout the study period.

Exclusion criteria

Exclusion Criteria:

  1. Known history of to the study drug formulation or any of its components;
  2. Intolerance to subcutaneous injection or other local skin abnormalities or dermatoses that may affect drug administration or safety assessment;
  3. Meeting any one of the following criteria during screening:

    1. \<60 g/L;
    2. count \<100×10⁹/L;
    3. Abnormal hepatic or renal function: (ALT) or aspartate aminotransferase (AST) ≥2.5× (ULN), or total ≥1.5× ULN; or serum creatinine (Cr) ≥1.5× ULN;
    4. Positive for anti- (HIV) antibodies.
  4. Any bleeding disorder other than congenital Factor VII deficiency, or other conditions causing significantly abnormal coagulation parameters (e.g., hemophilia A or B, von Willebrand disease, platelet disorders, vitamin K deficiency, etc.);
  5. Protein C deficiency or Protein S deficiency;
  6. History of thrombosis, family history of thrombosis, or history of thrombophilia;
  7. Intracranial hemorrhage within 2 years prior to signing the form;
  8. Severe cardiac disease, such as unstable angina, congestive heart failure ( class ≥III), serious arrhythmia ( >450 ms, corrected by Fridericia formula), uncontrolled hypertension (systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg), etc.;
  9. Female patients with menstrual abnormalities caused by organic gynecological conditions (e.g., uterine fibroids, endometriosis, adenomyosis, etc.);
  10. Received Factor VII-containing products within 48 hours prior to first administration of SR604 Injection; received whole blood or plasma transfusion within 2 weeks prior to first administration of SR604 Injection;
  11. Used any anticoagulants, antifibrinolytics, or agents affecting platelet function (including chemical drugs, biological products, or traditional Chinese medicine), including aspirin, within 1 week prior to screening, or required use of such agents during the treatment period;
  12. Underwent major surgery (defined as Grade III or IV surgery) within 1 month prior to signing the informed consent form, or planned to undergo surgery during the study period;
  13. Enrolled in other clinical trials within 1 month prior to signing the informed consent form;
  14. Miscarriage or pregnancy termination within 3 months prior to signing the informed consent form; pregnant or breastfeeding women;
  15. Mental illness or significant psychiatric disorder, or incapacity or lack of cognitive ability due to other causes;
  16. Other conditions deemed by the investigator to be unsuitable for enrollment, such as alcoholism, anticipated poor subject compliance preventing completion of dosing and study follow-up, poorly controlled comorbid chronic diseases, or serious systemic diseases.

    -

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    SR604:Multiple-dose exploratory efficacy trial consists of 2 cohorts

    Participants with FVII deficiency will receive SR604 dose 1/2 as multiple SC injections every 4-weeks

    Drug: SR604

Interventions

  • DrugSR604

    SR604 will be administered as SC injection.

06

What researchers measure

Primary outcomes

  1. Treated overall Annualized Bleeding Rate (ABR)

    Time frame: Through 28 weeks of treatment.

Secondary outcomes

  1. Treated spontaneous annualized bleeding rate

    Time frame: over 28 weeks of treatment

  2. Treated overall annualized joint bleeding rate

    Time frame: over 28 weeks of treatment

  3. Overall annualized bleeding rate including treated and untreated bleeding events

    Time frame: over 28 weeks of treatment,

  4. Annualized menorrhagia bleeding rate (menstruating females only)

    Time frame: over 28 weeks of treatment

  5. Change in PBAC score (menstruating females only);

    Time frame: From baseline over 28 weeks of treatment

  6. Change in EQ-5D-5L health index score

    Time frame: From pre-treatment over 28 weeks of treatment

  7. Change in EQ-VAS score

    Time frame: From baseline over 28 weeks of treatment;

  8. Subject overall satisfaction score with treatment efficacy

    Time frame: over 28 weeks of treatment

Other outcomes

  1. Single-dose pharmacokinetic (PK) parameters:Time to Peak Plasma Concentration (Tmax)

    Time frame: over 28 weeks of treatment

  2. Single-dose pharmacokinetic (PK) parameters:Peak Plasma Concentration (Cmax)

    Time frame: over 28 weeks of treatment

  3. Single-dose pharmacokinetic (PK) parameters:Area Under the Concentration-Time Curve from Zero to Last Quantifiable Time Point (AUC0-t)

    Time frame: over 28 weeks of treatment

  4. Multiple-dose pharmacokinetic parameters-Time to Peak Plasma Concentration (Tmax)

    Time frame: over 28 weeks of treatment

  5. Multiple-dose pharmacokinetic parameters-Peak Plasma Concentration (Cmax)

    Time frame: Over 28 weeks of treatment

  6. Safety and Immunogenicity:Incidence of AEs/SAEs/AESI,

    Time frame: over 28 weeks of treatment

  7. Incidence of drug-related AEs/SAEs/AESIs

    Time frame: over 28 weeks of treatment

  8. Safety and Immunogenicity: Anti-drug antibody (ADA) and neutralizing antibody (NAb) - number of subjects and incidence rate.

    Time frame: over 28 weeks of treatment

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Feb 2027, 7 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2026
First posted
Jul 17, 2026
StartEst.
Jul 2026
Primary completionEst.
Feb 2027
CompletionEst.
Dec 2027
Last update
Jul 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07711158
Responsible party
Sponsor
First posted
Jul 17, 2026
Start date
Jul 2026 (estimated)
Primary completion
Feb 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Jul 17, 2026

Study contacts

Research and Development
Contact
hanyu@raas-corp.com
862122130888

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SR604

Start the discussion